Judith I Tsui1, Brian G Leroux2, Andrea C Radick3, Zachery A Schramm4, Kendra Blalock4, Colleen Labelle5, Matthew Heerema5, Jared W Klein4, Joseph O Merrill4, Andrew J Saxon6, Jeffrey H Samet5, Theresa W Kim5. 1. Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA, 98104, USA. Electronic address: tsuij@uw.edu. 2. Department of Biostatistics, University of Washington, Seattle, WA, USA. 3. Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA, 98104, USA; Department of Biostatistics, University of Washington, Seattle, WA, USA. 4. Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA, 98104, USA. 5. Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center Boston, MA, USA. 6. Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Health Care System, Seattle, WA, USA.
Abstract
BACKGROUND: We conducted a pilot study to assess feasibility of using video directly-observed therapy (DOT) for patients initiating buprenorphine to evaluate whether it is associated with better opioid use disorder (OUD) outcomes when compared to treatment-as-usual (TAU). METHODS: Pilot randomized controlled trial of adult patients with OUD initiating buprenorphine treatment (n = 78) at two sites (Seattle, WA and Boston, MA) from January 2019 to May 2020. Intervention was video DOT using a HIPAA-compliant smartphone application to record taking daily buprenorphine. Study smartphones, text reminders to upload a video, and calendar summaries of video DOT adherence were provided. Main outcomes were 1) percentage of 12 weekly urine drug tests (UDT) negative for illicit opioids and 2) engagement in treatment at week 12 (i.e., having an active prescription for buprenorphine within the last 7 days). RESULTS: Of 78 enrolled, 20 (26 %) were female; 29 (37 %) non-white; and 31 (40 %) homeless. The mean (standard deviation) percentage of doses confirmed by video was 31 % (34 %). In intention-to-treat analysis, the average percentage of weekly opioid negative UDT was 50 % (95 % CI: 40-63 %) in the intervention arm versus 64 % (95 % CI: 55-74 %) among controls; RR = 0.78 (95 % CI: 0.60-1.02, p = 0.07). Engagement at week 12 was 69 % (95 % CI: 56-86 %) v. 82 % (95 % CI: 71-95 %) in the intervention vs. TAU arms, respectively; RR = 0.84 (95 % CI: 0.65-1.10, p = 0.20). CONCLUSIONS: The video DOT intervention did not result in improvements in illicit opioid use and treatment engagement compared to TAU. The study was limited by low rates of intervention use. TRIAL REGISTRATION: ClinicalTrails.gov, NCT03779997, Registered on December 19, 2018.
BACKGROUND: We conducted a pilot study to assess feasibility of using video directly-observed therapy (DOT) for patients initiating buprenorphine to evaluate whether it is associated with better opioid use disorder (OUD) outcomes when compared to treatment-as-usual (TAU). METHODS: Pilot randomized controlled trial of adult patients with OUD initiating buprenorphine treatment (n = 78) at two sites (Seattle, WA and Boston, MA) from January 2019 to May 2020. Intervention was video DOT using a HIPAA-compliant smartphone application to record taking daily buprenorphine. Study smartphones, text reminders to upload a video, and calendar summaries of video DOT adherence were provided. Main outcomes were 1) percentage of 12 weekly urine drug tests (UDT) negative for illicit opioids and 2) engagement in treatment at week 12 (i.e., having an active prescription for buprenorphine within the last 7 days). RESULTS: Of 78 enrolled, 20 (26 %) were female; 29 (37 %) non-white; and 31 (40 %) homeless. The mean (standard deviation) percentage of doses confirmed by video was 31 % (34 %). In intention-to-treat analysis, the average percentage of weekly opioid negative UDT was 50 % (95 % CI: 40-63 %) in the intervention arm versus 64 % (95 % CI: 55-74 %) among controls; RR = 0.78 (95 % CI: 0.60-1.02, p = 0.07). Engagement at week 12 was 69 % (95 % CI: 56-86 %) v. 82 % (95 % CI: 71-95 %) in the intervention vs. TAU arms, respectively; RR = 0.84 (95 % CI: 0.65-1.10, p = 0.20). CONCLUSIONS: The video DOT intervention did not result in improvements in illicit opioid use and treatment engagement compared to TAU. The study was limited by low rates of intervention use. TRIAL REGISTRATION: ClinicalTrails.gov, NCT03779997, Registered on December 19, 2018.
Authors: David A Fiellin; Michael V Pantalon; Marek C Chawarski; Brent A Moore; Lynn E Sullivan; Patrick G O'Connor; Richard S Schottenfeld Journal: N Engl J Med Date: 2006-07-27 Impact factor: 91.245
Authors: Yih-Ing Hser; Andrew J Saxon; David Huang; Al Hasson; Christie Thomas; Maureen Hillhouse; Petra Jacobs; Cheryl Teruya; Paul McLaughlin; Katharina Wiest; Allan Cohen; Walter Ling Journal: Addiction Date: 2013-10-09 Impact factor: 6.526
Authors: Zev Schuman-Olivier; Hilary Connery; Margaret L Griffin; Steve A Wyatt; Alan A Wartenberg; Jacob Borodovsky; John A Renner; Roger D Weiss Journal: Am J Addict Date: 2013-04-11
Authors: Margo E Godersky; Andrew J Saxon; Joseph O Merrill; Jeffrey H Samet; Jane M Simoni; Judith I Tsui Journal: Addict Sci Clin Pract Date: 2019-03-13
Authors: Kristina M Brooks; Jose R Castillo-Mancilla; Mary Morrow; Samantha MaWhinney; Sarah E Rowan; David Wyles; Joshua Blum; Ryan Huntley; Lana M Salah; Arya Tehrani; Lane R Bushman; Peter L Anderson; Jennifer J Kiser Journal: Open Forum Infect Dis Date: 2020-11-19 Impact factor: 4.423
Authors: Zachery A Schramm; Brian G Leroux; Andrea C Radick; Alicia S Ventura; Jared W Klein; Jeffrey H Samet; Andrew J Saxon; Theresa W Kim; Judith I Tsui Journal: Addict Sci Clin Pract Date: 2020-07-31
Authors: R S Garfein; K Collins; F Muñoz; K Moser; P Cerecer-Callu; F Raab; P Rios; A Flick; M L Zúñiga; J Cuevas-Mota; K Liang; G Rangel; J L Burgos; T C Rodwell; K Patrick Journal: Int J Tuberc Lung Dis Date: 2015-09 Impact factor: 2.373